Acumen Pharmaceuticals (NASDAQ:ABOS) Rating Increased to Hold at Wall Street Zen

Acumen Pharmaceuticals (NASDAQ:ABOS) was upgraded by research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued on Sunday.

A number of other research analysts have also weighed in on the company. BTIG Research reissued a “buy” rating and set a $8.00 price target on shares of Acumen Pharmaceuticals in a research note on Thursday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Acumen Pharmaceuticals in a research report on Friday, January 9th. Three research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $6.67.

Acumen Pharmaceuticals Stock Performance

Shares of NASDAQ ABOS opened at $2.26 on Friday. The company has a 50-day simple moving average of $2.70 and a 200-day simple moving average of $2.16. The company has a debt-to-equity ratio of 0.29, a current ratio of 6.02 and a quick ratio of 6.02. The company has a market cap of $136.89 million, a PE ratio of -1.12 and a beta of 0.21. Acumen Pharmaceuticals has a 12 month low of $0.86 and a 12 month high of $3.60.

Acumen Pharmaceuticals (NASDAQ:ABOS) last announced its quarterly earnings data on Thursday, March 26th. The company reported ($0.41) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.50) by $0.09. The firm had revenue of ($0.09) million for the quarter. On average, equities analysts anticipate that Acumen Pharmaceuticals will post -1.56 earnings per share for the current year.

Insider Transactions at Acumen Pharmaceuticals

In related news, CEO Daniel Joseph Oconnell sold 37,755 shares of the business’s stock in a transaction that occurred on Wednesday, January 7th. The shares were sold at an average price of $1.99, for a total value of $75,132.45. Following the completion of the sale, the chief executive officer directly owned 619,982 shares in the company, valued at approximately $1,233,764.18. The trade was a 5.74% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have sold 149,818 shares of company stock valued at $285,057 in the last ninety days. 9.30% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Acumen Pharmaceuticals

A number of large investors have recently bought and sold shares of ABOS. Jacobs Levy Equity Management Inc. acquired a new position in shares of Acumen Pharmaceuticals in the 3rd quarter valued at $27,000. Marex Group plc purchased a new position in shares of Acumen Pharmaceuticals in the 2nd quarter worth $39,000. Independent Advisor Alliance purchased a new position in shares of Acumen Pharmaceuticals in the 4th quarter worth $40,000. PFG Investments LLC boosted its holdings in Acumen Pharmaceuticals by 65.2% in the fourth quarter. PFG Investments LLC now owns 19,000 shares of the company’s stock valued at $40,000 after acquiring an additional 7,500 shares during the last quarter. Finally, Marshall Wace LLP acquired a new position in Acumen Pharmaceuticals in the fourth quarter valued at $44,000. Hedge funds and other institutional investors own 71.01% of the company’s stock.

Key Stories Impacting Acumen Pharmaceuticals

Here are the key news stories impacting Acumen Pharmaceuticals this week:

• Positive Sentiment: Acumen said it has $36M of funding to advance its EBD program and is targeting an ALTITUDE‑AD Phase II readout in late 2026 — this provides program funding visibility and a clear clinical milestone that could re‑rate shares if results are favorable. Acumen targets ALTITUDE-AD Phase II readout in late 2026 while advancing EBD program with $36M funding
• Positive Sentiment: BTIG Research reaffirmed a “buy” rating and set an $8 price target, suggesting sizable upside from current levels and giving institutional validation to the company’s clinical strategy. BTIG buy rating and $8 price target coverage
• Positive Sentiment: Q4 results beat on the EPS line (reported $(0.41) vs. $(0.50) consensus), showing a smaller-than-expected loss and suggesting modest operating leverage as programs advance. Acumen Q4 EPS beat and earnings materials
• Neutral Sentiment: Company press release and earnings‑call highlights outlined strategic advances and program updates (full-year financials and business highlights), which provide context but no immediate new financing or partnership decisions. Q4 2025 Earnings Call Highlights
• Neutral Sentiment: Full-year 2025 financial report reiterates cash burn, program priorities and R&D focus — useful for modeling runway but not a catalyst by itself. Acumen reports financial results and business highlights
• Negative Sentiment: Acumen filed to sell 10.83 million shares of common stock on behalf of holders — a potential secondary that increases near‑term supply and dilution risk, which likely pressured the stock despite operational positives. Acumen files to sell 10.83M shares for holders

About Acumen Pharmaceuticals

Acumen Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of oral small molecule therapies for neurodegenerative diseases. Leveraging a proprietary drug discovery platform that integrates chemoproteomics, high-throughput screening and computational chemistry, the company seeks to identify and optimize compounds that selectively modulate pathological protein aggregation. Its approach is designed to address the underlying biology of conditions such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis and related proteinopathies.

The company’s pipeline comprises multiple lead candidates at various stages of preclinical and early clinical development.